Drug Trial Radar · NCT04644029
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
730
Actual
Start
Feb 24, 2021
Primary completion
Jul 18, 2023
Study completion Jun 11, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 16 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections.
Conditions
- HIV-I
- Human Immunodeficiency Virus Type 1
- Prophylaxis
Interventions
IslatravirDrug
Oral 60 mg tablet administered once monthly during Part 1.
Placebo to FTC/TDFDrug
0 mg tablet administered once daily during Part 1.
FTC/TDFDrug
Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
Placebo to ISLDrug
0 mg tablet administered orally once monthly in Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-BlindTime frame: Up to approximately 325 days
- Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-BlindTime frame: Up to approximately 325 days
- Number of Participants Who Discontinued Blinded Study Treatment Due to an AETime frame: Up to 283 days
Locations
24 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064)
Birmingham, Alabama
MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si
Washington D.C., District of Columbia
University of Miami Miller School of Medicine-Infectious Disease ( Site 0076)
Miami, Florida
Orlando Immunology Center ( Site 0068)
Orlando, Florida
Ponce De Leon Center Grady Health ( Site 0066)
Atlanta, Georgia
The University of Mississippi Medical Center ( Site 0065)
Jackson, Mississippi
KC CARE Health Center-Clinical Trials ( Site 0059)
Kansas City, Missouri
Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071)
Newark, New Jersey
Bronx Prevention Center ICAP ( Site 0062)
The Bronx, New York
The University of North Carolina at Chapel Hill-Medicine ( Site 0056)
Chapel Hill, North Carolina
Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069)
Columbia, South Carolina
Prism Health North Texas, Oak Cliff Health Center ( Site 0070)
Dallas, Texas
West Virginia University-Department of Medicine ( Site 0061)
Morgantown, West Virginia
Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023)
Johannesburg, Gauteng, South Africa
Wits Reproductive Health and HIV Institute (WRHI)-Wits RHI Ward 21 Clinical Research site ( Site 002
Johannesburg, Gauteng, South Africa
Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0020)
Johannesburg, Gauteng, South Africa
Setshaba Research Centre ( Site 0016)
Pretoria, Gauteng, South Africa
SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0030)
Chatsworth, KwaZulu-Natal, South Africa
Maternal Adolescent and Child Health Research (MatCH) ( Site 0025)
Durban, KwaZulu-Natal, South Africa
Qhakaza Mbokodo Research Clinic ( Site 0017)
Ladysmith, KwaZulu-Natal, South Africa
Madibeng Centre for Research ( Site 0019)
Brits, North West, South Africa
Aurum Institute Klerksdorp CRS ( Site 0029)
Klerksdorp, North West, South Africa
Aurum Institute - Rustenburg ( Site 0022)
Rustenburg, North West, South Africa
MU-JHU Care Limited-Clinic ( Site 0041)
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.